Cognos Therapeutics
Cognos Therapeutics
Stealth ModeCognos Therapeutics is developing a novel therapeutic approach for neurodegenerative diseases.
Rate
About
Cognos Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic approach for neurodegenerative diseases. Their lead product candidate, CG-001, is designed to target the underlying pathology of diseases such as Alzheimer's and Parkinson's. The company aims to bring a disease-modifying therapy to patients who currently have limited treatment options.
Technology stack
detected 2026-07-03Emailnone
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does Cognos Therapeutics do?
Cognos Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic approach for neurodegenerative diseases. Their lead product candidate, CG-001, is designed to target the underlying pathology of diseases such as Alzheimer's and Parkinson's. The company aims to bring a disease-modifying therapy to patients who currently have limited treatment options.
Where is Cognos Therapeutics headquartered?
Cognos Therapeutics is headquartered in Tel Aviv, Israel.
What industry does Cognos Therapeutics operate in?
Cognos Therapeutics operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials, Neurotech.